ClinicalTrials.gg
CompletedNCT06790225GINEBRAUpdated Oct 1, 2026

Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)

An interventional study of Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Disease, Metabolic, Diabetes Mellitus, Type 2 and Obesity and Obesity-related Medical Conditions, sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark · Not applicable, Interventional, and Basic science

How we know

Updated Oct 1, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Bone Diseases, Metabolic with a site in Denmark — 2 open to participants now, 5 under way, none of them phase 3. Bone Diseases, Metabolic · Denmark.

Enrollment
22nd of 23
13 · median 85
Started
2025
with 2 others
No phase
9 of 26
1 open now
Registered
24th of 26
by date
Lead sponsor
1 of 26
Esbjerg Hospital - University Hospital of Southern Denmark

Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 24th registered.

Bone Diseases, Metabolic

663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

2 of the 26 studies in Bone Diseases, Metabolic with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Bone Diseases, Metabolic with a site in Denmark, or all of them as a file.
02

Study summary

Glucose-dependent insulinotropic polypeptide (GIP) is released by the intestines in response to food intake and increases insulin secretion. Although short-term (\< 3 hours) stimulation with GIP decreases bone resorption in humans, the effect may vanish following continuous administration within 24 hours, at least in patients with type 1 diabetes. Whether the anti-resorptive effect of GIP can be maintained if the hormone is non-continuously administrated is unclear. As the first GIP receptor (GIPR) agonist, tirzepatide was recently approved for the treatment of obesity and type 2 diabetes in the USA and type 2 diabetes alone in the EU, there is a need to establish knowledge about the long-term effects of GIP on bone health, including if different exposure times to GIP have different skeletal effects.

This project will investigate whether GIP maintains its anti-resorptive potential if given as intermittent compared to continuous infusion in healthy men and women aged 18-40 years. Administration cycles involve intermittent (8 hours daily) and continuous (24 hours daily) injection of GIP for three days each. The effect of GIP will be measured by bone markers in blood samples, as well as in vitro activity and genetic alterations of bone cells (osteoclasts and osteoblasts) using bone marrow aspirates and bone marrow biopsies. Each participant will receive both administration cycles using a crossover design with a 14-28 days washout period between administrations of GIP.

03

Conditions studied

  • Bone Disease, Metabolic
  • Diabetes Mellitus, Type 2
  • Obesity and Obesity-related Medical Conditions

Keywords

  • GIP
  • CTX
  • P1NP
  • Glucose-dependent insulinotropic polypeptide
  • Bone remodelling
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy volunteers

Exclusion criteria

Exclusion Criteria:

  • pre-diabetes or diabetes ( >42mmol/mol)
  • >28
  • fractures with \< 6months
  • comorbidities/treatments that may influence bone metabolism or procedures - -- pregnancy
  • inability to provide informed concent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Intermittent then continious

    The participants that recive the intermittent administration first, followed by the continious

    Other: Glucose-dependent Insulinotropic Polypeptide (GIP)

  • Experimental
    Continious then intermittent

    The participants that recives the continious administration first, follwoed by the intermittent

    Other: Glucose-dependent Insulinotropic Polypeptide (GIP)

Interventions

  • OtherGlucose-dependent Insulinotropic Polypeptide (GIP)

    Recombinant human GIP (1-42)

06

What researchers measure

Primary outcomes

  1. Serum levels of CTX

    Serum levels of CTX (bone resorption marker) will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)

    Time frame: During a three day period. With 14-28 days of washout between the two administration methods

Secondary outcomes

  1. Serum levels of osteocalcin and P1NP

    Serum levels of osteocalcin and P1NP (bone formation markers) will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)

    Time frame: During a three day period. With 14-28 days of washout between the two administration methods

  2. Serum levels of GIP

    Serum levels of GIP will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)

    Time frame: During a three day period. With 14-28 days of washout between the two administration methods

07

Study locations

1 site
  • University hospital of Southern Denmark
    Esbjerg, 6700, Denmark
08

References and documents

Individual participant data

Plan to share: No — individual participant data will not be shared following GDPR and local data mangament regulation. However data(anonymous) and results will be published once the study is completed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Sep 2026, 10 months.

Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 10 months is below that.

Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Nov 2026 → Sep 2026 and completion Nov 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 24, 2025
StartActual
Nov 10, 2025
Primary completionActual
Sep 17, 2026was Nov 2026
CompletionActual
Sep 17, 2026was Nov 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 1, 2026
Primary completion
Nov 1, 2026→Sep 17, 2026 (actual)
Oct 1, 2026
Study completion
Nov 30, 2027→Sep 17, 2026 (actual)
Oct 1, 2026
Enrollment
12 (estimated)→13 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Completed
    Primary completion Nov 1, 2026→Sep 17, 2026 (now actual)
    Study completion Nov 30, 2027→Sep 17, 2026 (now actual)
    Enrollment 12 (estimated)→13 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06790225
Lead sponsor
Esbjerg Hospital - University Hospital of Southern Denmark
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Nov 10, 2025
Primary completion
Sep 17, 2026
Completion
Sep 17, 2026
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion